Secondary outcome: clinical flare · adults with eczema
1 finding from 1 review
Secondary outcome 3. Number of eczema flares, measured by, for example, ‘escalation of treatment’ or ‘use of topical anti‐inflammatory medications’ Amount of 0.1% hydrocortisone butyrate cream used during the study · adults with eczema
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Moderate
Secondary outcome: clinical flare · adults with eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: clinical flare · adults with eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: clinical flare · children with eczema
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
1 finding from 1 review
Clinical cure · participants with confirmed toenail onychomycosis
Azole probably leads to lower clinical cure compared with terbinafine (moderate certainty).
1 finding from 1 review
Quality of life · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical cure · participants with confirmed toenail onychomycosis
Azole leads to higher clinical cure compared with placebo (high certainty).
1 finding from 1 review
Mycological cure · participants with confirmed toenail onychomycosis
Azole leads to higher mycological cure compared with placebo (high certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Azole showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Recurrence · participants with confirmed toenail onychomycosis
Azole showed no clear difference in recurrence rate compared with placebo (low certainty).
1 finding from 1 review
Quality of life · participants with confirmed toenail onychomycosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical cure · participants with confirmed toenail onychomycosis
Griseofulvin showed no clear difference in clinical cure compared with azole (moderate certainty).
1 finding from 1 review
Mycological cure · participants with confirmed toenail onychomycosis
Griseofulvin showed no clear difference in mycological cure compared with azole (moderate certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Griseofulvin probably leads to higher adverse events compared with azole (moderate certainty).
1 finding from 1 review